BioInvent Extends Manufacturing Services ContractBy
BioInvent International, a Lund, Sweden-based pharmaceutical company focused on antibody-based anti-cancer drugs, has extended its contract for manufacturing services with a major global pharmaceutical client. The extension covers services for one of the products in the pharmaceutical company's development portfolio. This new agreement is expected to generate about SEK 8 million ($945,000) in revenue, with the majority occurring in 2016.
During the year, BioInvent strengthened its ability to independently produce antibodies by investing in a single use bioreactor. The company's production facility has the capacity to produce antibodies, both for research purposes and for clinical trials all the way through to Phase III.
Source: BioInvent International